1. AstraZeneca pays Sobi $95M for priority review voucher — Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study — Retrophin sinks as drug “Pharma Bro” Martin Shkreli co-invented fails — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Who's interviewing

Discussion in 'Zogenix' started by Anonymous, Mar 22, 2015 at 10:45 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Well Im happy to still have a job with Pernix while I look for the next opportunity. What are everyones thoughts? Are you interviewing? Planning on making a go of it with Pernix? What?
     
  2. Anonymous

    Anonymous Guest

    Who isn't interviewing? Are you really that dumb?
     
  3. Anonymous

    Anonymous Guest

    well I wish I could say that I had some hope but I dont think Pernix is any more capable of making Zohydro successful than Zogenix was. Im not convinced that they can do much about the MC situation despite their beleif that they can. I dont want to look for a job again as I have only been here a little over a year and dont want to appear to be job hopping but I dont feel like I have much choice.
     
  4. Anonymous

    Anonymous Guest

    that hope isn't worth a caffe latte at Starbucks. Listen and listen closely dumbass. Start interviewing.
     
  5. Anonymous

    Anonymous Guest

    yeah listen closely dumbass hes smart and knows everything. What is ya, ignant?
     
  6. Anonymous

    Anonymous Guest

    How many SAM's are left after all of the "non- viable" territory BS layoffs?
     
  7. Anonymous

    Anonymous Guest

    2